Search

Objectives. Unknown onset stroke (UOS) is usually excluded from intravenous thrombolysis concerning the unclear symptom onset time. Attempts have been done to use thrombolytic therapy in these patients. The current meta-analysis was done to examine the efficacy and safety of intravenous thrombolysis in UOS. Methods. PubMed, Web of Science, and Cochrane Library were searched for studies comparing thrombolysis with conservative therapy among UOSs. Data of good outcome (mRS, 0-2), mortality, and intracerebral hemorrhage (ICH) and symptomatic ICH (sICH) were extracted and analyzed using the Revman 5.2 software. Results. In total, 8 studies with 1271 subjects (542 with thrombolysis and 729 with conservative therapy) were included in this meta-analysis. The data showed that patients receiving thrombolysis had a higher incidence of 90-day good outcome (P=0.0005) than conservative therapy. The comparison of discharge (P=0.89) and 90-day mortality (P=0.10) in both groups did not find any significances. The incidences of ICH (P=0.42) and sICH (P=0.06) were relatively comparable between the two therapies. Conclusions. Intravenous thrombolysis is a better choice for UOS patients for its efficacy and safety. In addition, pretreatment imaging assessment is beneficial for improving the efficacy of thrombolytic therapy. However, it needs more supporting evidences for clinical use in the future.

NADC34-like porcine reproductive and respiratory syndrome virus (PRRSV) has become endemic in some provinces of China and caused huge economic losses to local pig industry. The increased reports of NADC34-like PRRSV outbreaks in vaccinated pig herds suggest the limited protection of immunization with commercial vaccines. In this study, we evaluated a commercial PRRSV vaccine that has been widely used in China against the challenge of JS2021NADC34 PRRSV, a highly pathogenic Chinese NADC34-like strain isolated in 2021. The vaccinated pigs developed PRRSV-specific antibody responses, as shown by IDEXX ELISA results. After JS2021NADC34 PRRSV challenge, the vaccinated pigs had low level of viremia but suffered pathological lesions in lungs and lymphoid tissues. The viral antigens were also detected in the above tissues of the vaccinated pigs by immunohistochemistry staining. One out of five pigs in vaccinated group died at 13 days postchallenge. The above results suggested that the commercial PRRSV vaccine could not provide complete protection to the NADC34-like PRRSV infection. [ABSTRACT FROM AUTHOR]